Laman UtamaMOLN • NASDAQ
add
Molecular Partners AG
Tutup sebelumnya
$4.28
Julat hari
$4.20 - $4.24
Julat tahun
$3.36 - $5.56
Permodalan pasaran
160.39J USD
Bilangan Purata
4.51K
Nisbah P/E
-
Hasil dividen
-
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (CHF) | Sep 2025info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 3.60J | -18.25% |
Pendapatan bersih | -11.84J | 27.85% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -0.33 | 32.65% |
EBITDA | -11.40J | 18.54% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (CHF) | Sep 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 104.52J | -27.22% |
Jumlah aset | 112.15J | -27.27% |
Jumlah liabiliti | 16.62J | 7.70% |
Jumlah ekuiti | 95.53J | — |
Syer tertunggak | 37.40J | — |
Harga kepada buku | 1.68 | — |
Pulangan pada aset | -25.23% | — |
Pulangan pada modal | -29.02% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (CHF) | Sep 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -11.84J | 27.85% |
Tunai daripada operasi | -9.93J | 25.27% |
Tunai daripada pelaburan | 10.66J | -25.01% |
Tunai daripada pembiayaan | -304.00K | -1.00% |
Perubahan bersih dalam tunai | 384.00K | 481.82% |
Aliran tunai bebas | -5.40J | 33.24% |
Perihal
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Diasaskan
2004
Tapak web
Pekerja
153
